CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 291 enrolled
Drug / intervention
CG5503 IR +2 moredrug
Likely dose
CG5503 IR 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00609466
NCT00609466Phase 3Completed

A Randomized, Double-blind, Parallel-group, Multi-center, Active- and Placebo-controlled Trial to Evaluate the Analgesic Efficacy and Safety of Multiple Doses of CG5503 IR for Postoperative Pain Following Bunionectomy

Grünenthal GmbH·interventional·Posted Feb 7, 2008·Updated Nov 16, 2011

In Brief

A Phase 3 clinical trial evaluating CG5503 IR, Morphine, and 1 other intervention for Bunionectomy and 3 related conditions. Completed, enrolled 291 participants across 6 sites.

Detailed Summary

The main objective of this trial is to demonstrate the efficacy and safety of multiple-dose application of oral application of CG5503 IR 75mg compared to placebo and to assess safety and tolerability of CG5503 IR 75mg in subjects following bunionectomy. This trial was performed based on a previously performed double-blind, placebo-controlled, multiple-dose trial in the same indication investigating 3 dose strengths CG5503 IR (50, 75 and 100 mg) published under PMID: 18851776.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 7, 2008
Enrollment StartSep 1, 2007
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.4 years ago

Interventions

CG5503 IRdrug

75mg IR 4 - 6 hourly Total: 72 hours

Morphinedrug

Morphine 30 mg IR 4 - 6 hourly Total: 72 hours

Placebodrug

Placebo; 4 - 6 hourly; Total: 72 hours